Avtor/Urednik		Binbrek, Azan S; Elis, Avishay; Al-Zaibag, Muayed; Eha, Jaan; Keber, Irena; Cuevas, Ada M; Mukherjee, Swati; Miller, Thomas R
Naslov		Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open-label, parallel-group, multicenter study (DISCOVERY alpha study)
Tip		članek
Vir		Curr Ther Res Clin Exp
Vol. in št.		Letnik 67, št. 1
Leto izdaje		2006
Obseg		str. 21-41
Jezik		eng
Abstrakt		Background: The majority of clinical trials investigating the clinical benefits of lipid-lowering therapies (LLTs) have focused on North American or western and nothern European populations. Therefore, it is timely to confirm the efficacy of these agents in other patient populations in routine clinical practice. Objective: The aim of the DIrect Statin COmparison of low-density lipoprotein cholesterol (LDL-C) Values: an Evaluation of Rosuvastatin therapY (DISCOVERY) Alpha study was to compare the effects of rosuvastatin 10 mg with those of atorvastatin 10 mg in achieving LDL-C goals in the Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice guidelines. Methods: This randomized, open-label, parallel-group study was conducted at 93 centers in eastern Europe (Estonia, Latvia, Romania, Russia, Slovenia), Central and South America (Chile, Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua, Panama), and the Middle East (Israel, Kuwait, Saudi Arabia, United Arab Emirates). Male and female patients aged >-18 years with primary hypercholesterolemia (LDL-C level, >135 mg/dL if LLT-naive or >-120 mg/dL if switching statins; triglyceride [TG) level, <400 mg/dL) and a 10-year coronary heart disease (CHD) risk >20% or a history of CHD or other established atherosclerotic disease were eligible for inclusion in the study. Patients were randomly assigned to receive rosuvastatin 10-mg tablets QD for 12 weeks. No formal statistical analyses or comparisons were performed on lipid changes between switched and LLT-naive patients because of the different lipid inclusion criteria for these patients. (Abstract truncated at 2000 characters)
Deskriptorji		HYPERCHOLESTEROLEMIA LIPOPROTEINS, LDL CHOLESTEROL ANTILIPEMIC AGENTS CORONARY DISEASE TRIGLYCERIDES MULTICENTER STUDIES RANDOMIZED CONTROLLED TRIALS TREATMENT OUTCOME